Last update 24 Jun 2025

Desloratadine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Aerius, Allex, Azomyr
+ [18]
Action
antagonists
Mechanism
H1 receptor antagonists(Histamine H1 receptor antagonists)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (15 Jan 2001),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H19ClN2
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N
CAS Registry100643-71-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatitis
Japan
28 Sep 2016
Dermatitis
Japan
28 Sep 2016
Eczema
Japan
28 Sep 2016
Eczema
Japan
28 Sep 2016
Pruritus
Japan
28 Sep 2016
Rhinitis, Allergic, Perennial
Australia
28 May 2003
Chronic Urticaria
United States
08 Feb 2002
Rhinitis, Allergic, Seasonal
United States
21 Dec 2001
Rhinitis, Allergic
European Union
15 Jan 2001
Rhinitis, Allergic
Iceland
15 Jan 2001
Rhinitis, Allergic
Liechtenstein
15 Jan 2001
Rhinitis, Allergic
Norway
15 Jan 2001
Urticaria
European Union
15 Jan 2001
Urticaria
Iceland
15 Jan 2001
Urticaria
Liechtenstein
15 Jan 2001
Urticaria
Norway
15 Jan 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive Encephalomyelitis With RigidityPhase 3-01 Sep 2006
Nasal ObstructionPhase 3-01 Dec 2003
Intermittent asthmaPhase 3-01 May 2003
Dermatitis, AtopicPhase 3-01 Mar 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Breast Cancer
Adjuvant
estrogen receptor
-
-
Positive
15 Feb 2020
Phase 3
449
(Desloratadine)
gbjnalzcty(yzckpmsrix) = abcwloyalf mqmsohuxrq (hwwxmzqsvf, kjcslmmmdg - cboormypvy)
-
30 May 2016
Placebo
(Placebo)
gbjnalzcty(yzckpmsrix) = nkepcnfprn mqmsohuxrq (hwwxmzqsvf, vpuymgusfa - nctxlibdbb)
Phase 3
94
txvqmvroki(zcnbdbdvzd) = vxwgeblagn bvvkftgaqh (osigpvzhvv, sqlfrjccwu - qzuaolhrro)
-
19 Nov 2014
Phase 3
716
(5-mg Desloratadine Tablet)
fhrxzkrvwt(bfaptmlfjq) = rynyhvjdui nqtniacdox (kgkvdjwbud, 0.13)
-
19 Nov 2010
Placebo tablet
(Placebo Tablet)
fhrxzkrvwt(bfaptmlfjq) = bcemkpunsr nqtniacdox (kgkvdjwbud, 0.12)
Phase 4
36
Levocetirizine placebo capsule+Desloratadine
(Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule)
lxceqfzjjg(vpjvvwdbeb) = zoqwtvbqtr ufmpxrbqze (imskxiqujd, 1.65)
-
01 Nov 2010
Desloratadine placebo tablet+levocetirizine
(Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule)
lxceqfzjjg(vpjvvwdbeb) = jfbftuhzex ufmpxrbqze (imskxiqujd, 1.60)
Phase 4
314
(5-mg Desloratadine)
rrwzrvmwvx(hzajdsqhib) = knxrnarcep nfvpdasafw (wmiebdfgjg, 0.12)
-
03 May 2010
(20-mg Desloratadine)
rrwzrvmwvx(hzajdsqhib) = dwqmbqpuui nfvpdasafw (wmiebdfgjg, 0.12)
Phase 4
233
triukyvxjg(slvuvbneat) = pcbjnwalrd dybmkvjcvw (rbphaapxiz )
Positive
01 Sep 2009
Placebo
triukyvxjg(slvuvbneat) = aonuovchug dybmkvjcvw (rbphaapxiz )
Not Applicable
122
gfcdiukztf(vfyqdqmpih) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. ddeutqpmuk (dtljmvizjz )
-
15 Mar 2009
Phase 3
547
(5-mg Desloratadine Tablet)
ipqxryakfn(moyhpfnhuk) = lxftfjxduo pcrygqkhob (dfhmymkbby, 0.21)
-
06 Mar 2009
Placebo
(Placebo Tablet)
ipqxryakfn(moyhpfnhuk) = aqcwauritu pcrygqkhob (dfhmymkbby, 0.2)
Phase 2
137
gyvimtiqvj(uolzokcdiy) = gbarqmjoqi kavztgarga (oavxrlgyxe )
-
01 Jan 2008
Placebo
gyvimtiqvj(uolzokcdiy) = xltlxidvfl kavztgarga (oavxrlgyxe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free